These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26991517)

  • 41. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
    Lammers LA; Achterbergh R; van Schaik RHN; Romijn JA; Mathôt RAA
    Clin Pharmacokinet; 2017 Oct; 56(10):1231-1244. PubMed ID: 28229374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
    Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
    Koo SH; Soon GH; Pruvost A; Benech H; Ang TL; Lee EJD; Ang DSW
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jul; 395(7):815-826. PubMed ID: 35394133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites.
    Tanaka S; Uchida S; Inui N; Takeuchi K; Watanabe H; Namiki N
    Biol Pharm Bull; 2014; 37(1):18-25. PubMed ID: 24389476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
    Snyder BD; Rowland A; Polasek TM; Miners JO; Doogue MP
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1115-22. PubMed ID: 25028073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
    Minocha M; Tran JQ; Sheridan JP; Othman AA
    Clin Pharmacokinet; 2016 Jan; 55(1):121-30. PubMed ID: 26242380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
    Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M
    Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
    Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
    J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
    Garimella T; Tao X; Sims K; Chang YT; Rana J; Myers E; Wind-Rotolo M; Bhatnagar R; Eley T; LaCreta F; AbuTarif M
    Drugs R D; 2018 Mar; 18(1):55-65. PubMed ID: 29255971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
    Othman AA; Tran JQ; Tang MT; Dutta S
    Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
    Tachibana M; Papadopoulos KP; Strickler JH; Puzanov I; Gajee R; Wang Y; Zahir H
    Br J Clin Pharmacol; 2018 Jan; 84(1):112-121. PubMed ID: 28865153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers.
    Kim DS; Kim Y; Jeon JY; Kim MG
    J Ginseng Res; 2016 Oct; 40(4):375-381. PubMed ID: 27746690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.
    Zadoyan G; Rokitta D; Klement S; Dienel A; Hoerr R; Gramatté T; Fuhr U
    Eur J Clin Pharmacol; 2012 May; 68(5):553-60. PubMed ID: 22189672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
    Zheng L; Lu Y; Cao X; Huang Y; Liu Y; Tang L; Liao SG; Wang AM; Li YJ; Lan YY; Wang YL
    J Ethnopharmacol; 2014 Dec; 158 Pt A():276-82. PubMed ID: 25446640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.